170 related articles for article (PubMed ID: 34789127)
1. Unfolded p53 as a Marker of Oxidative Stress in Mild Cognitive Impairment, Alzheimer's and Parkinson's Disease.
García S; Amor-Gutiérrez O; Palomares-Albarrán M; Toyos-Rodríguez C; Cuetos F; Martínez C; Costa-García A; Fernández-Sánchez MT; de la Escosura-Muñiz A; Novelli A
Curr Alzheimer Res; 2021; 18(9):695-700. PubMed ID: 34789127
[TBL] [Abstract][Full Text] [Related]
2. Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer's disease.
Amor-Gutiérrez O; Costa-Rama E; Arce-Varas N; Martínez-Rodríguez C; Novelli A; Fernández-Sánchez MT; Costa-García A
Anal Chim Acta; 2020 Jan; 1093():28-34. PubMed ID: 31735212
[TBL] [Abstract][Full Text] [Related]
3. Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment.
Stanga S; Lanni C; Sinforiani E; Mazzini G; Racchi M
Curr Alzheimer Res; 2012 Dec; 9(10):1191-7. PubMed ID: 22746246
[TBL] [Abstract][Full Text] [Related]
4. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
5. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.
Dursun E; Gezen-Ak D; Hanağası H; Bilgiç B; Lohmann E; Ertan S; Atasoy İL; Alaylıoğlu M; Araz ÖS; Önal B; Gündüz A; Apaydın H; Kızıltan G; Ulutin T; Gürvit H; Yılmazer S
J Neuroimmunol; 2015 Jun; 283():50-7. PubMed ID: 26004156
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease.
Fujino T; Hossain MS; Mawatari S
Adv Exp Med Biol; 2020; 1299():195-212. PubMed ID: 33417216
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer's and Mild Cognitive Impairment Patients.
Arce-Varas N; Abate G; Prandelli C; Martínez C; Cuetos F; Menéndez M; Marziano M; Cabrera-García D; Fernández-Sánchez MT; Novelli A; Memo M; Uberti D
Curr Alzheimer Res; 2017; 14(1):112-122. PubMed ID: 27748187
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.
Gündüztepe Y; Bukan N; Zorlu E; Karaman Y; Andaç Topkan T; Gurbuz N; Neşelioğlu S; Erel Ö
J Clin Neurosci; 2020 May; 75():188-194. PubMed ID: 32223973
[TBL] [Abstract][Full Text] [Related]
9. Increases of pentraxin 3 plasma levels in patients with Parkinson's disease.
Lee HW; Choi J; Suk K
Mov Disord; 2011 Nov; 26(13):2364-70. PubMed ID: 21953577
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
11. Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease.
King E; O'Brien J; Donaghy P; Williams-Gray CH; Lawson RA; Morris CM; Barnett N; Olsen K; Martin-Ruiz C; Burn D; Yarnall AJ; Taylor JP; Duncan G; Khoo TK; Thomas A
Int J Geriatr Psychiatry; 2019 Aug; 34(8):1244-1250. PubMed ID: 30993722
[TBL] [Abstract][Full Text] [Related]
12. Cognitive impairment in Parkinson's disease is multifactorial: A neuropsychological study.
Smith CR; Cullen B; Sheridan MP; Cavanagh J; Grosset KA; Grosset DG
Acta Neurol Scand; 2020 Jun; 141(6):500-508. PubMed ID: 32002988
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
Mattsson-Carlgren N; Janelidze S; Palmqvist S; Cullen N; Svenningsson AL; Strandberg O; Mengel D; Walsh DM; Stomrud E; Dage JL; Hansson O
Brain; 2020 Dec; 143(11):3234-3241. PubMed ID: 33068398
[TBL] [Abstract][Full Text] [Related]
14. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
Chiu MJ; Yang SY; Horng HE; Yang CC; Chen TF; Chieh JJ; Chen HH; Chen TC; Ho CS; Chang SF; Liu HC; Hong CY; Yang HC
ACS Chem Neurosci; 2013 Dec; 4(12):1530-6. PubMed ID: 24090201
[TBL] [Abstract][Full Text] [Related]
15. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.
Goldman JG; Aggarwal NT; Schroeder CD
Neurodegener Dis Manag; 2015 Oct; 5(5):425-43. PubMed ID: 26517759
[TBL] [Abstract][Full Text] [Related]
16. Conformationally altered p53: a novel Alzheimer's disease marker?
Lanni C; Racchi M; Mazzini G; Ranzenigo A; Polotti R; Sinforiani E; Olivari L; Barcikowska M; Styczynska M; Kuznicki J; Szybinska A; Govoni S; Memo M; Uberti D
Mol Psychiatry; 2008 Jun; 13(6):641-7. PubMed ID: 17684496
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and BDNF serum levels.
Siuda J; Patalong-Ogiewa M; Żmuda W; Targosz-Gajniak M; Niewiadomska E; Matuszek I; Jędrzejowska-Szypułka H; Lewin-Kowalik J; Rudzińska-Bar M
Neurol Neurochir Pol; 2017; 51(1):24-32. PubMed ID: 28341039
[TBL] [Abstract][Full Text] [Related]
18. Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment.
Becker S; Boettinger O; Sulzer P; Hobert MA; Brockmann K; Maetzler W; Berg D; Liepelt-Scarfone I;
J Alzheimers Dis; 2021; 79(1):197-209. PubMed ID: 33216023
[TBL] [Abstract][Full Text] [Related]
19. SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients.
Begic E; Hadzidedic S; Kulaglic A; Ramic-Brkic B; Begic Z; Causevic M
PLoS One; 2019; 14(2):e0212261. PubMed ID: 30763368
[TBL] [Abstract][Full Text] [Related]
20. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease.
Lanni C; Racchi M; Stanga S; Mazzini G; Ranzenigo A; Polotti R; Memo M; Govoni S; Uberti D
J Alzheimers Dis; 2010; 20(1):97-104. PubMed ID: 20164600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
